Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Saddam Hassan
lecturer of Nephrology
Nephrology UNIT
Benha University
saddamnephro@yahoo.com
Metformin Lakes
“ From Bench to Bedside “
Glomerular or Tubuloglomerular?
“ Conventional Paradigm “
Does Benefit justify Risk ?
“ Opportun...
“ From Bench to Bedside “
Glomerular or Tubuloglomerular?
The 5-Staged model of DKD
A1 A2 A3
T1DM Natural History
 Albuminuria (A2)
“Micro”:
 Highly Variable:
(Ontarget)
Spontan.regression (30%).
 “Non-Proteinuric”
Phenotype (30%)/
R...
A1 A2 A3
Cr-Based eGFR
U-shaped Mortality Curve
 Low eGFR:
 CVD + Renal Mortality(1)
 High eGFR
(Hyperfiltration):
 CV...
Biomarker?
Functional vs Structural
(RPS Classif.2010)
The 5-Staged model of DKD
Biomarker?
(RPS Classif.2010)
∆𝐴𝐸𝑅 ≠
∆Biopsy
∆GFR
A new player in the town
?
“Verifying Biopsy”
CRIC study
In search of new Biomarkers…
“Epigenetics”
“ From Bench to Bedside
“
Glomerular or Tubuloglomerular?
“Glomerulo”/centric
DKD
“TubuloGlomerular DKD”
Albuminuria: “The Holy Grail
“?
“ From Bench to Bedside
“
Glomerular or Tubuloglomerular?
SGLT2:
 S1 PCT
 low-affinity
 high-capacity
 90%
Gl.Absorb.
SGLT1:
 S2,3
PCT/GIT
 High-affinity
 Low-capacity
TubuloGlo...
TubuloGlomerular Feddback:
“ Cross Talks“?
TubuloGlomerular Feddback:
“ Cross Talks“ ?
TubuloGlomerular Feddback:
“ Cross Talks“ ?
TubuloGlomerular Feddback:
“ Cross Talks“ ?
TubuloGlomerular Feddback:
“ Salt Paradox“?
Richard Gilbert KI 2013
“Tubulo”/centric DN
“Tubulopathic DKD ?”
Volker Vallon
Nephron Clin Pract
2014
“ From Bench to Bedside “
One-size-fits-all Approach?
“ Conventional Paradigm “
Number-tunneled vs Patient-centered?
“ Opp...
Conventional
wisdom:
RAAS Blockade:
The Mantra ?Target Dose?
Salt restriction
Dual Blockade
VDR
Analogues
Sara Roscioni Nature Nephrology 2...
RAAS Blockade:
“Challenging the Dogma?”
OnTarget:
Telmisartan
+ Ramipril
Va –Nephron:
Losartan+
Lisinopril
Altitude:
Alisk...
You Are What You Eat ?
“Salt Paradox”
David Charytan &
John Forman
KI 2012
RAAS Blockade:
Optimizing the response
?
RAAS BLOCKADE:
The Holy Grail?
“Opposite View”
 “Imperfect ?”
 Breakthrough/Escape
“phenomenon”
 Non-proteinuric Progre...
BP Targets:
Less prescriptive & More Personalized!
Uric Acid ?
wisdom:
“Challenging the
Dogma?”
You Are What You Eat ?
“ Sweet Debate ”
Dysglycemia
?
 AKI.
 CKD.
Glycemic Control:
“Monitoring= eAG”
 Glycated Haemoglobin?
 Longer duration
 Surrogate used in major Trials
 Glycated ...
Glycemic Control:
“Monitoring”
 HBA1c!!
90 day mortality: IIT:(27.5%), CIT: (24.9%)
Absolute mortality difference: 2.6%
Odds ratio for death with IIT was 1.14 .
G...
Short-term
HYPERGLYCEMIA:
“ DYSGLYCEMIC PEAKS“?
Glycemic Control:
CKD
“Act Now or Pay Later”
Mortality & HbA1c
 U-shaped curve
HbA1c ( ) 6.5% -- 9 %
 CKD-ND
(Arch Inte...
All-cause mortality
23,618 DM on Hd
Glycemic Control:
“Act Now >> T1DM:
DCCT/EDIC”
Glycemic Control:
“Act Now >> T2DM: UKPDS”
Holman NEJM 2008
Posthoc
Subgroup
Analysis
“Intensive Glycemic Control”:
Do the Benefits justify the Risks
?
Excess
ALL-Cause/
CVD mortalit...
Act Now !
 Metabolic Memory?
 (UKPDS)
 Legacy effect?
 (DCCT/EDIC)
 microRNAs?
Pay Later !
 Burnt out DKD ?
 (ACC...
 Age
 B.W
 Complication
 Duration
 Expectancy
ADA/AHA position statement 2014:
Skyler (Diabetes Care 2009)
You Are What You Lose
?
 “Weight Reduction”
NODAT
NODAT
Adnan Sharif and Keshwar Baboolal 2012, Nature reviews
NODAT
Metformin:
Reappraisal
SGLT2i:
New Promises
“Crescedence”0
wisdom:
“Challenging the
Dogma?”
(1 B) : CKD-ND & RTx : Statin +/- Ezetimibe.
Posthoc
Subgroup
Analysis
MACE
reduction
Not
Renal
endpoints
Negative outcome...
KDOKI 2012 :
(1 B) : CKD-ND & CKD-RTx : Statin +/- Ezetimibe.
(1B) : CKD-D: Non-Start Non-Stop Policy
“Not to initiate” !
...
CKD-D: Non-Start Non-Stop Policy
“Not to initiate” (1B) !
Low
“signal to noise”
phenemenon
Lipid management:
Diabetogenicity of
Statins
“ From Bench to Bedside “
One-size-fits-all Approach?
“ Conventional Paradigm “
Number-tunneled vs Patient-centered?
“ Opp...
MSPB ?
Multiple Signal Pathway
Blockade?
Pleiotropic?
context -
specific
limited?
Beatriz et al., Nature Reviews 2014
Novel Approaches to DKD
Pleiotropic?
context -
specific
limited?
Novel Approaches to DKD
In Summary….
 Care
for
Glomerulus
but
Mind the
Tubules !
Diabetic kidney disease " Challenging the Dogma"
Diabetic kidney disease " Challenging the Dogma"
Diabetic kidney disease " Challenging the Dogma"
Diabetic kidney disease " Challenging the Dogma"
Diabetic kidney disease " Challenging the Dogma"
Diabetic kidney disease " Challenging the Dogma"
Diabetic kidney disease " Challenging the Dogma"
Diabetic kidney disease " Challenging the Dogma"
Diabetic kidney disease " Challenging the Dogma"
Diabetic kidney disease " Challenging the Dogma"
Diabetic kidney disease " Challenging the Dogma"
Diabetic kidney disease " Challenging the Dogma"
Upcoming SlideShare
Loading in …5
×

Diabetic kidney disease " Challenging the Dogma"

907 views

Published on

  • Login to see the comments

Diabetic kidney disease " Challenging the Dogma"

  1. 1. Saddam Hassan lecturer of Nephrology Nephrology UNIT Benha University saddamnephro@yahoo.com
  2. 2. Metformin Lakes
  3. 3. “ From Bench to Bedside “ Glomerular or Tubuloglomerular? “ Conventional Paradigm “ Does Benefit justify Risk ? “ Opportunities or Challenges “ Multi-Pathway Signal Blockade ?
  4. 4. “ From Bench to Bedside “ Glomerular or Tubuloglomerular?
  5. 5. The 5-Staged model of DKD A1 A2 A3 T1DM Natural History
  6. 6.  Albuminuria (A2) “Micro”:  Highly Variable: (Ontarget) Spontan.regression (30%).  “Non-Proteinuric” Phenotype (30%)/ RIACE (55%>>> F/CVD)  Low Specificity: Competing risk (MACE & MAKE)  Renal Endpoint? (ME Molitch et al. KI 2014)  Albuminuria (A1) “Normo”:  High Normal UAER: Increased risk of MACE/MAKE! (Babazono et al. Diabetes Care 2009) A1 A2 A3
  7. 7. A1 A2 A3 Cr-Based eGFR U-shaped Mortality Curve  Low eGFR:  CVD + Renal Mortality(1)  High eGFR (Hyperfiltration):  CVD Mortality(2) Cyst.C-Based eGFR Better predicts  death & prog. to ESRD(3) (ME Molitch et al., KI 2014) (Fox et al., Lancet 2012) (de Boer et al., Diab Care 2009)
  8. 8. Biomarker? Functional vs Structural (RPS Classif.2010)
  9. 9. The 5-Staged model of DKD Biomarker? (RPS Classif.2010) ∆𝐴𝐸𝑅 ≠ ∆Biopsy ∆GFR
  10. 10. A new player in the town ? “Verifying Biopsy”
  11. 11. CRIC study
  12. 12. In search of new Biomarkers… “Epigenetics”
  13. 13. “ From Bench to Bedside “ Glomerular or Tubuloglomerular?
  14. 14. “Glomerulo”/centric DKD “TubuloGlomerular DKD”
  15. 15. Albuminuria: “The Holy Grail “?
  16. 16. “ From Bench to Bedside “ Glomerular or Tubuloglomerular?
  17. 17. SGLT2:  S1 PCT  low-affinity  high-capacity  90% Gl.Absorb. SGLT1:  S2,3 PCT/GIT  High-affinity  Low-capacity TubuloGlomerular Feddback: “ Cross Talks “? Tahrani et al. Lancet 2011
  18. 18. TubuloGlomerular Feddback: “ Cross Talks“?
  19. 19. TubuloGlomerular Feddback: “ Cross Talks“ ?
  20. 20. TubuloGlomerular Feddback: “ Cross Talks“ ?
  21. 21. TubuloGlomerular Feddback: “ Cross Talks“ ?
  22. 22. TubuloGlomerular Feddback: “ Salt Paradox“? Richard Gilbert KI 2013
  23. 23. “Tubulo”/centric DN “Tubulopathic DKD ?” Volker Vallon Nephron Clin Pract 2014
  24. 24. “ From Bench to Bedside “ One-size-fits-all Approach? “ Conventional Paradigm “ Number-tunneled vs Patient-centered? “ Opportunities or Challenges “ Multi-Pathway Signal Blockade
  25. 25. Conventional wisdom:
  26. 26. RAAS Blockade: The Mantra ?Target Dose? Salt restriction Dual Blockade VDR Analogues Sara Roscioni Nature Nephrology 2013
  27. 27. RAAS Blockade: “Challenging the Dogma?” OnTarget: Telmisartan + Ramipril Va –Nephron: Losartan+ Lisinopril Altitude: Aliskirin
  28. 28. You Are What You Eat ? “Salt Paradox” David Charytan & John Forman KI 2012
  29. 29. RAAS Blockade: Optimizing the response ?
  30. 30. RAAS BLOCKADE: The Holy Grail? “Opposite View”  “Imperfect ?”  Breakthrough/Escape “phenomenon”  Non-proteinuric Progressors  Ischemic Nephropathy (25-30%).  “Deleterious ?” :  Early: AKI ”s” !! (Ontarget)/)(Roadmap)  Late: SORO-ESRD !! (Maculay Ongabli/Nahas) Macaulay Onuigbo Nephron Clin Pract 2011
  31. 31. BP Targets: Less prescriptive & More Personalized!
  32. 32. Uric Acid ?
  33. 33. wisdom: “Challenging the Dogma?”
  34. 34. You Are What You Eat ? “ Sweet Debate ”
  35. 35. Dysglycemia ?  AKI.  CKD.
  36. 36. Glycemic Control: “Monitoring= eAG”  Glycated Haemoglobin?  Longer duration  Surrogate used in major Trials  Glycated Albumin?  Fructosamine (AlbF)? Contin. Gluc. Monitoring(CGM) (Marijn Speeckaert et al., ERPB, NDT, 2014)
  37. 37. Glycemic Control: “Monitoring”  HBA1c!!
  38. 38. 90 day mortality: IIT:(27.5%), CIT: (24.9%) Absolute mortality difference: 2.6% Odds ratio for death with IIT was 1.14 . Glycemic Control: in AKI: “ NICE SUGAR ”
  39. 39. Short-term HYPERGLYCEMIA: “ DYSGLYCEMIC PEAKS“?
  40. 40. Glycemic Control: CKD “Act Now or Pay Later” Mortality & HbA1c  U-shaped curve HbA1c ( ) 6.5% -- 9 %  CKD-ND (Arch Intern Med 2011)  CKD5-HD (Diabetes care 2012)  CKD5-PD DOPPS (JASN 2011) & (KI 2012)  HbA1c > 8% pretransplant Tx ?? (Molnar et al. Diabetes Care 2011) Observational studies
  41. 41. All-cause mortality 23,618 DM on Hd
  42. 42. Glycemic Control: “Act Now >> T1DM: DCCT/EDIC”
  43. 43. Glycemic Control: “Act Now >> T2DM: UKPDS” Holman NEJM 2008
  44. 44. Posthoc Subgroup Analysis “Intensive Glycemic Control”: Do the Benefits justify the Risks ? Excess ALL-Cause/ CVD mortality Munehro et al., WJD,2014 Soft Surrogates
  45. 45. Act Now !  Metabolic Memory?  (UKPDS)  Legacy effect?  (DCCT/EDIC)  microRNAs? Pay Later !  Burnt out DKD ?  (ACCORD).  (ADVANCE/ON).  (VADT). Glycemic Control: “Act Now or Pay Later”
  46. 46.  Age  B.W  Complication  Duration  Expectancy ADA/AHA position statement 2014: Skyler (Diabetes Care 2009)
  47. 47. You Are What You Lose ?  “Weight Reduction”
  48. 48. NODAT
  49. 49. NODAT Adnan Sharif and Keshwar Baboolal 2012, Nature reviews
  50. 50. NODAT
  51. 51. Metformin: Reappraisal SGLT2i: New Promises “Crescedence”0
  52. 52. wisdom: “Challenging the Dogma?”
  53. 53. (1 B) : CKD-ND & RTx : Statin +/- Ezetimibe. Posthoc Subgroup Analysis MACE reduction Not Renal endpoints Negative outcomes: 4D AURORA SHARP CKD-D: Non-Start Non-Stop Policy “Not to initiate” (1B) !
  54. 54. KDOKI 2012 : (1 B) : CKD-ND & CKD-RTx : Statin +/- Ezetimibe. (1B) : CKD-D: Non-Start Non-Stop Policy “Not to initiate” ! Posthoc Subgroup Analysis MACE reduction Not Renal endpoints
  55. 55. CKD-D: Non-Start Non-Stop Policy “Not to initiate” (1B) ! Low “signal to noise” phenemenon
  56. 56. Lipid management: Diabetogenicity of Statins
  57. 57. “ From Bench to Bedside “ One-size-fits-all Approach? “ Conventional Paradigm “ Number-tunneled vs Patient-centered? “ Opportunities or Challenges “ Multi-Pathway Signal Blockade
  58. 58. MSPB ? Multiple Signal Pathway Blockade? Pleiotropic? context - specific limited?
  59. 59. Beatriz et al., Nature Reviews 2014 Novel Approaches to DKD
  60. 60. Pleiotropic? context - specific limited? Novel Approaches to DKD
  61. 61. In Summary….  Care for Glomerulus but Mind the Tubules !

×